What Is Orexin A? Structure, Receptors and Literature

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

Orexin A is one of the better-documented neuropeptides in this catalogue, and it has an unusual bibliographic quirk: it has two names, because two laboratories reported the system independently in 1998. Anyone searching the literature needs both. Searching “orexin” alone misses the hypocretin papers, and vice versa.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

The molecule

Property	Value
Length	33 residues
Alternative name	Hypocretin-1
Disulfide bridges	Two, intrachain
N-terminus	Pyroglutamate
C-terminus	Amidated
Precursor	Prepro-orexin, also yields orexin B
Receptors	OX1R and OX2R

Two disulfide bridges in a 33-residue peptide is a structurally demanding arrangement. Four cysteines can pair in three different ways, only one of which is correct, and all three give the same molecular mass. This is the single most important handling fact about orexin A: a mass spectrum confirming the expected value does not confirm that the disulfides are correctly paired. Chromatographic separation is what distinguishes the correct isomer from the alternatives.

Both termini are also modified. The pyroglutamate blocks aminopeptidase attack and the amidated C-terminus blocks carboxypeptidases, so the native peptide arrives with its ends already protected — the same arrangement seen in gonadorelin and in several other native neuropeptides.

Discovery and the two-name problem

The 1998 paper by Sakurai and colleagues in Cell is the canonical citation. It reported the peptides and their receptors together, named them orexins after an association with feeding behaviour, and established the family. The independent report from the other group named the same peptides hypocretins, after their hypothalamic origin and a sequence resemblance to secretin.

The practical consequence for literature work is simple and consequential: the two names are used in different sub-fields, with the sleep and clinical diagnostic literature favouring hypocretin and the pharmacology literature favouring orexin. A search strategy using one term returns a systematically biased slice of the field.

Receptor pharmacology

Orexin A binds both OX1R and OX2R with broadly comparable affinity. Orexin B is reported as preferring OX2R. That asymmetry is the main handle available for separating the two peptides pharmacologically, and it shapes how experiments in the field are designed.

The 2021 chapter by Sun and colleagues in Frontiers of Neurology and Neuroscience is the most direct source on receptor pharmacology in relation to sleep phases. The 2020 review by Li and colleagues in Neuropharmacology takes the circuitry view instead — where the orexin neurons are, what they project to, and what that implies. Read together, the two reviews cover the receptor level and the systems level, and the gap between them is where most unresolved questions in the field sit.

The analytical literature is unusually useful here

Hypocretin-1 measurement in cerebrospinal fluid is an established laboratory assay, which means orexin A has something most research peptides lack: a body of published work on measuring it accurately.

The 2025 paper by Vialaret and colleagues in Sleep is a good example. It concerns a 16-mer form of hypocretin-1/orexin-A in cerebrospinal fluid, which is to say it is about distinguishing the intact peptide from a fragment in a real biological matrix. For anyone developing an assay or validating material, this is more directly useful than the pharmacology literature:

Question	Where to look
What does the peptide do?	Sakurai 1998; Li 2020
Which receptor, and how selectively?	Sun 2021
How is it measured reliably?	Vialaret 2025
Is my material the right isomer?	Chromatogram on the certificate

Handling

A 33-residue, doubly disulfide-bridged, partly hydrophobic peptide needs more care than a short linear one.

Aliquot on first reconstitution, without exception. Repeated freezing and thawing promotes disulfide scrambling and aggregation in a peptide of this architecture.
Avoid reducing agents in the diluent. Any thiol-containing buffer component will attack the disulfides. This rules out several common additives that are harmless for linear peptides.
Expect surface adsorption at low concentration. Peptides of this size and hydrophobicity are lost to tube and pipette surfaces; a carrier protein is used routinely where the experiment permits it.
Do not vortex vigorously. Shear and foaming promote unfolding and aggregation. Swirl gently.
Request the chromatogram. For a two-disulfide peptide, the purity number alone cannot distinguish correct from incorrect pairing. See how to read a certificate of analysis.

Concentration maths should start from net peptide content rather than gross vial weight. Our reconstitution calculator takes the molecular weight and net mass from the certificate, which for a 33-residue peptide is a larger absolute correction than for a hexapeptide.

Our orexin A research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report.

Scope note

This material is supplied for laboratory research use only. It is not a medicine, not a supplement, and not for human or veterinary use. The content above concerns peptide structure, receptor identity, literature navigation and handling chemistry.

Open questions

How much of the published orexin literature uses material with verified disulfide pairing?
What is the functional significance of the fragment forms detected in cerebrospinal fluid?
Can OX1R- and OX2R-mediated effects be separated cleanly with available peptide tools?

Frequently asked questions

What is orexin A?

A 33-residue neuropeptide, also called hypocretin-1, derived from a precursor that also yields orexin B. It carries two intrachain disulfide bridges, a pyroglutamate N-terminus and an amidated C-terminus, and it acts at two G protein-coupled receptors, OX1R and OX2R.

Why does orexin A have two names?

Two groups reported the system independently in 1998, one naming the peptides orexins after an observed association with feeding, the other naming them hypocretins after their hypothalamic origin and resemblance to secretin. Both names remain in use, and searching one alone misses part of the literature.

What receptors does it act on?

Two: OX1R and OX2R. Orexin A binds both with comparable affinity, whereas orexin B is reported as more selective for OX2R. That difference is the main pharmacological distinction between the two peptides.

What makes orexin A difficult to handle?

Its structure. Two disulfide bridges in a 33-residue peptide mean a specific folded form has to be preserved, and incorrect pairing produces isomers of identical mass. It is also strongly hydrophobic in parts, which contributes to surface adsorption at low concentration.

Is orexin A used as an analytical reference?

Yes. Hypocretin-1 measurement in cerebrospinal fluid is an established diagnostic assay, and recent work on the 16-mer fragment reflects continuing method development. That literature is a good source of information on the peptide’s analytical behaviour.

References

Sakurai T, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998. PMID: 9491897 https://pubmed.ncbi.nlm.nih.gov/9491897/
Li SB, et al. The hypocretin (orexin) system: from a neural circuitry perspective. Neuropharmacology. 2020. PMID: 32135427 https://pubmed.ncbi.nlm.nih.gov/32135427/
Sun Y, et al. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci. 2021. PMID: 34052813 https://pubmed.ncbi.nlm.nih.gov/34052813/
Vialaret J, et al. 16-mer hypocretin-1/orexin-A in cerebrospinal fluid to diagnose narcolepsy. Sleep. 2025. PMID: 40801283 https://pubmed.ncbi.nlm.nih.gov/40801283/